Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Amortization of Deferred Charges (2016 - 2025)

Historic Amortization of Deferred Charges for Regen BioPharma (RGBPP) over the last 10 years, with Q4 2025 value amounting to $8850.0.

  • Regen BioPharma's Amortization of Deferred Charges fell 2997.86% to $8850.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $48359.0, marking a year-over-year increase of 33332.53%. This contributed to the annual value of $52148.0 for FY2025, which is 27983.31% up from last year.
  • As of Q4 2025, Regen BioPharma's Amortization of Deferred Charges stood at $8850.0, which was down 2997.86% from $34234.0 recorded in Q3 2025.
  • Regen BioPharma's Amortization of Deferred Charges' 5-year high stood at $34234.0 during Q3 2025, with a 5-year trough of -$42043.0 in Q3 2024.
  • For the 5-year period, Regen BioPharma's Amortization of Deferred Charges averaged around $6954.6, with its median value being $4436.0 (2022).
  • As far as peak fluctuations go, Regen BioPharma's Amortization of Deferred Charges soared by 526304.35% in 2022, and later plummeted by 496608.8% in 2024.
  • Quarter analysis of 5 years shows Regen BioPharma's Amortization of Deferred Charges stood at $22451.0 in 2021, then tumbled by 80.24% to $4436.0 in 2022, then fell by 1.56% to $4367.0 in 2023, then soared by 189.42% to $12639.0 in 2024, then decreased by 29.98% to $8850.0 in 2025.
  • Its last three reported values are $8850.0 in Q4 2025, $34234.0 for Q3 2025, and -$7364.0 during Q2 2025.